Silvan Tuerkcan
Stock Analyst at Citizens JMP
(4.71)
# 731
Out of 4,517 analysts
418
Total ratings
43.6%
Success rate
17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintained: Buy | $8 → $11 | $5.97 | +84.25% | 44 | Jun 23, 2026 | |
| RLAY Relay Therapeutics | Maintained: Buy | $19 → $21 | $19.37 | +8.42% | 37 | May 20, 2026 | |
| ENGN enGene Therapeutics | Downgraded: Hold | n/a | $1.92 | - | 7 | May 8, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | $28 → $30 | $11.86 | +152.95% | 45 | Apr 28, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Buy | $86 → $80 | $48.57 | +64.71% | 56 | Jan 30, 2026 | |
| NUVB Nuvation Bio | Maintained: Buy | $8 → $10 | $5.64 | +77.30% | 6 | Nov 20, 2025 | |
| BNTC Benitec Biopharma | Maintained: Buy | $20 → $22 | $12.66 | +73.78% | 26 | Nov 4, 2025 | |
| FHTX Foghorn Therapeutics | Maintained: Buy | $9 | $5.07 | +77.51% | 4 | Oct 31, 2025 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $45 | $35.93 | +25.24% | 4 | Oct 13, 2025 | |
| JSPR Jasper Therapeutics | Maintained: Buy | $12 → $6 | $0.774 | +675.19% | 12 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $1.75 | +642.86% | 12 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $9.05 | +65.75% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.12 | - | 29 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $55.68 | -10.20% | 53 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $3.22 | n/a | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.6146 | n/a | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $17.34 | n/a | 31 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $2.67 | n/a | 23 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.00001 | n/a | 7 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $12.10 | n/a | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.88 | n/a | 3 | May 7, 2020 |
Taysha Gene Therapies
Jun 23, 2026
Maintained: Buy
Price Target: $8 → $11
Current: $5.97
Upside: +84.25%
Relay Therapeutics
May 20, 2026
Maintained: Buy
Price Target: $19 → $21
Current: $19.37
Upside: +8.42%
enGene Therapeutics
May 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.92
Upside: -
Intellia Therapeutics
Apr 28, 2026
Maintained: Buy
Price Target: $28 → $30
Current: $11.86
Upside: +152.95%
CRISPR Therapeutics AG
Jan 30, 2026
Maintained: Buy
Price Target: $86 → $80
Current: $48.57
Upside: +64.71%
Nuvation Bio
Nov 20, 2025
Maintained: Buy
Price Target: $8 → $10
Current: $5.64
Upside: +77.30%
Benitec Biopharma
Nov 4, 2025
Maintained: Buy
Price Target: $20 → $22
Current: $12.66
Upside: +73.78%
Foghorn Therapeutics
Oct 31, 2025
Maintained: Buy
Price Target: $9
Current: $5.07
Upside: +77.51%
IDEAYA Biosciences
Oct 13, 2025
Reiterated: Buy
Price Target: $45
Current: $35.93
Upside: +25.24%
Jasper Therapeutics
Sep 22, 2025
Maintained: Buy
Price Target: $12 → $6
Current: $0.774
Upside: +675.19%
Sep 17, 2025
Reiterated: Buy
Price Target: $13
Current: $1.75
Upside: +642.86%
Sep 12, 2025
Reiterated: Buy
Price Target: $15
Current: $9.05
Upside: +65.75%
Aug 15, 2025
Reiterated: Hold
Price Target: n/a
Current: $4.12
Upside: -
Jul 29, 2025
Reiterated: Buy
Price Target: $50
Current: $55.68
Upside: -10.20%
Jun 18, 2025
Reiterated: Buy
Price Target: $6
Current: $3.22
Upside: n/a
Jun 3, 2025
Reiterated: Buy
Price Target: $4
Current: $0.6146
Upside: n/a
May 9, 2025
Downgraded: Hold
Price Target: n/a
Current: $17.34
Upside: n/a
Mar 14, 2025
Maintained: Buy
Price Target: $6
Current: $2.67
Upside: n/a
Dec 27, 2024
Rated: Hold
Price Target: n/a
Current: $0.00001
Upside: n/a
Jan 26, 2023
Maintained: Buy
Price Target: $18
Current: $12.10
Upside: n/a
May 7, 2020
Rated: Hold
Price Target: n/a
Current: $2.88
Upside: n/a